{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T20:08:53Z","timestamp":1743106133204,"version":"3.40.3"},"publisher-location":"Cham","reference-count":70,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030237646"},{"type":"electronic","value":"9783030237653"}],"license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-23765-3_2","type":"book-chapter","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T16:03:08Z","timestamp":1567267388000},"page":"71-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Experience with Bispecific T Cell Engagers"],"prefix":"10.1007","author":[{"given":"Nicola","family":"G\u00f6kbuget","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,1]]},"reference":[{"key":"2_CR1","doi-asserted-by":"crossref","unstructured":"Advani AS, Moseley A, O\u2019Dwyer KM, Wood B, Fang M, Wieduwilt MJ et al (2018) Results of SWOG 1318: a phase 2 trial of blinatumomab followed by pomp (prednisone, vincristine, methotrexate, 6-mercaptopurine) maintenance in elderly patients with newly diagnosed philadelphia chromosome negative B-cell acute lymphoblastic leukemia. Blood 132","DOI":"10.1182\/blood-2018-99-111992"},{"issue":"9","key":"2_CR2","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/ajh.24783","volume":"92","author":"I Aldoss","year":"2017","unstructured":"Aldoss I, Song J, Stiller T, Nguyen T, Palmer J, O\u2019Donnell M et al (2017) Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia. Am J Hematol 92(9):858\u2013865","journal-title":"Am J Hematol"},{"issue":"5891","key":"2_CR3","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S et al (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891):974\u2013977","journal-title":"Science"},{"issue":"7","key":"2_CR4","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH et al (2017) Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol 3(7):e170580","journal-title":"JAMA Oncol"},{"issue":"1","key":"2_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","volume":"129","author":"F Braig","year":"2017","unstructured":"Braig F, Brandt A, Goebeler M, Tony HP, Kurze AK, Nollau P et al (2017) Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood 129(1):100\u2013104","journal-title":"Blood"},{"issue":"10","key":"2_CR6","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00262-007-0298-z","volume":"56","author":"C Brandl","year":"2007","unstructured":"Brandl C, Haas C, d\u2019Argouges S, Fisch T, Kufer P, Brischwein K et al (2007) The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19\/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother 56(10):1551\u20131563","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"2_CR7","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.molimm.2005.07.034","volume":"43","author":"K Brischwein","year":"2006","unstructured":"Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R et al (2006) MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 43(8):1129\u20131143","journal-title":"Mol Immunol"},{"issue":"14","key":"2_CR8","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1182\/blood-2016-12-725804","volume":"129","author":"D Campana","year":"2017","unstructured":"Campana D, Pui CH (2017) Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia. Blood 129(14):1913\u20131918","journal-title":"Blood"},{"issue":"5053","key":"2_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1126\/science.1373518","volume":"256","author":"RH Carter","year":"1992","unstructured":"Carter RH, Fearon DT (1992) CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256(5053):105\u2013107","journal-title":"Science"},{"issue":"16","key":"2_CR10","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","volume":"115","author":"V Conter","year":"2010","unstructured":"Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A et al (2010) Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115(16):3206\u20133214","journal-title":"Blood"},{"issue":"1","key":"2_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2515135518763280","volume":"6","author":"E Dahlen","year":"2018","unstructured":"Dahlen E, Veitonmaki N, Norlen P (2018) Bispecific antibodies in cancer immunotherapy. Ther Adv Vaccines Immunother 6(1):3\u201317","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"6","key":"2_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/1078155217713363","volume":"24","author":"RK DasGupta","year":"2018","unstructured":"DasGupta RK, Marini BL, Rudoni J, Perissinotti AJ (2018) A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. J Oncol Pharm Pract 24(6):453\u2013467","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"2_CR13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/ijc.10557","volume":"100","author":"T Dreier","year":"2002","unstructured":"Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F et al (2002) Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 100(6):690\u2013697","journal-title":"Int J Cancer"},{"issue":"10","key":"2_CR14","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/leu.2017.41","volume":"31","author":"J Duell","year":"2017","unstructured":"Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A et al (2017) Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia 31(10):2181\u20132190","journal-title":"Leukemia"},{"issue":"47","key":"2_CR15","doi-asserted-by":"publisher","first-page":"76902","DOI":"10.18632\/oncotarget.12357","volume":"7","author":"J Feucht","year":"2016","unstructured":"Feucht J, Kayser S, Gorodezki D, Hamieh M, Doring M, Blaeschke F et al (2016) T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts. Oncotarget 7(47):76902\u201376919","journal-title":"Oncotarget"},{"issue":"3","key":"2_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.cbpa.2013.03.029","volume":"17","author":"SR Frankel","year":"2013","unstructured":"Frankel SR, Baeuerle PA (2013) Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 17(3):385\u2013392","journal-title":"Curr Opin Chem Biol"},{"issue":"20","key":"2_CR17","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O et al (2016) Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127(20):2406\u20132410","journal-title":"Blood"},{"issue":"5","key":"2_CR18","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","volume":"57","author":"ME Goebeler","year":"2016","unstructured":"Goebeler ME, Bargou R (2016) Blinatumomab: a CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leuk Lymphoma 57(5):1021\u20131032","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2_CR19","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","volume":"34","author":"ME Goebeler","year":"2016","unstructured":"Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H et al (2016) Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-hodgkin lymphoma: final results from a phase I study. J Clin Oncol 34(10):1104\u20131111","journal-title":"J Clin Oncol"},{"issue":"3","key":"2_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.beha.2017.07.010","volume":"30","author":"N G\u00f6kbuget","year":"2017","unstructured":"G\u00f6kbuget N (2017) How should we treat a patient with relapsed Ph-negative B-ALL and what novel approaches are being investigated? Best Pract Res Clin Haematol 30(3):261\u2013274","journal-title":"Best Pract Res Clin Haematol"},{"issue":"9","key":"2_CR21","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","volume":"120","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R et al (2012) Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 120(9):1868\u20131876","journal-title":"Blood"},{"issue":"9","key":"2_CR22","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1038\/bcj.2016.84","volume":"6","author":"N G\u00f6kbuget","year":"2016","unstructured":"G\u00f6kbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H et al (2016) Blinatumomab vs historical standard therapy of adult relapsed\/refractory acute lymphoblastic leukemia. Blood Cancer J 6(9):e473","journal-title":"Blood Cancer J"},{"key":"2_CR23","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C et al (2018a) Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia. Blood","DOI":"10.1182\/blood-2017-08-798322"},{"key":"2_CR24","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Dombret H, Zugmaier G, Bonifacio M, Graux C, Faul C et al (2018b) Blinatumomab for minimal residual disease (MRD) in adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL): median overall survival (OS) is not reached in complete MRD responders at a median follow-up of 53.1 months. Blood 132:554","DOI":"10.1182\/blood-2018-99-111516"},{"issue":"7","key":"2_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00262-003-0496-2","volume":"53","author":"M Gruen","year":"2004","unstructured":"Gruen M, Bommert K, Bargou RC (2004) T-cell-mediated lysis of B cells induced by a CD19\u00d7CD3 bispecific single-chain antibody is perforin dependent and death receptor independent. Cancer Immunol Immunother 53(7):625\u2013632","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"2_CR26","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF et al (2017) Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7(12):1404\u20131419","journal-title":"Cancer Discov"},{"issue":"1","key":"2_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.20908","volume":"115","author":"P Hoffmann","year":"2005","unstructured":"Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R et al (2005) Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct. Int J Cancer 115(1):98\u2013104","journal-title":"Int J Cancer"},{"issue":"9","key":"2_CR28","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1002\/ijc.25556","volume":"128","author":"SC Hoffmann","year":"2011","unstructured":"Hoffmann SC, Wabnitz GH, Samstag Y, Moldenhauer G, Ludwig T (2011) Functional analysis of bispecific antibody (EpCAMxCD3)-mediated T-lymphocyte and cancer cell interaction by single-cell force spectroscopy. Int J Cancer 128(9):2096\u20132104","journal-title":"Int J Cancer"},{"issue":"20","key":"2_CR29","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1002\/cncr.31720","volume":"124","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M et al (2018) Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer 124(20):4044\u20134055","journal-title":"Cancer"},{"issue":"8","key":"2_CR30","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W et al (2016) Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375(8):740\u2013753","journal-title":"N Engl J Med"},{"issue":"9","key":"2_CR31","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836\u2013847","journal-title":"N Engl J Med"},{"issue":"1","key":"2_CR32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/imr.12393","volume":"270","author":"M Klinger","year":"2016","unstructured":"Klinger M, Benjamin J, Kischel R, Stienen S, Zugmaier G (2016a) Harnessing T cells to fight cancer with BiTE(R) antibody constructs\u2013past developments and future directions. Immunol Rev 270(1):193\u2013208","journal-title":"Immunol Rev"},{"key":"2_CR33","doi-asserted-by":"crossref","unstructured":"Klinger M, Zugmaier G, Naegele V, Goebeler M, Brandl C, Bargou RC et al (2016b) Pathogenesis-based development of potential mitigation strategies for blinatumomab-associated neurologic events (NEs). Blood 128","DOI":"10.1182\/blood.V128.22.1589.1589"},{"key":"2_CR34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3389\/fonc.2018.00285","volume":"8","author":"S Kobold","year":"2018","unstructured":"Kobold S, Pantelyushin S, Rataj F, Vom Berg J (2018) Rationale for combining bispecific T cell activating antibodies with checkpoint blockade for cancer therapy. Front Oncol 8:285","journal-title":"Front Oncol"},{"issue":"43","key":"2_CR35","doi-asserted-by":"publisher","first-page":"E6649","DOI":"10.1073\/pnas.1611445113","volume":"113","author":"L Krshnan","year":"2016","unstructured":"Krshnan L, Park S, Im W, Call MJ, Call ME (2016) A conserved \u03b1\u03b2 transmembrane interface forms the core of a compact T-cell receptor-CD3 structure within the membrane. Proc Natl Acad Sci U S A 113(43):E6649\u2013E6658","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2_CR36","first-page":"10","volume":"1","author":"P Kufer","year":"2001","unstructured":"Kufer P, Zettl F, Borschert K, Lutterbuse R, Kischel R, Riethmuller G (2001) Minimal costimulatory requirements for T cell priming and TH1 differentiation: activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs. Cancer Immun 1:10","journal-title":"Cancer Immun"},{"key":"2_CR37","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1038\/bcj.2015.68","volume":"5","author":"GS Laszlo","year":"2015","unstructured":"Laszlo GS, Gudgeon CJ, Harrington KH, Walter RB (2015) T-cell ligands modulate the cytolytic activity of the CD33\/CD3 BiTE antibody construct, AMG 330. Blood Cancer J 5:e340","journal-title":"Blood Cancer J"},{"issue":"14","key":"2_CR38","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1158\/0008-5472.CAN-11-3912","volume":"72","author":"DT Le","year":"2012","unstructured":"Le DT, Jaffee EM (2012) Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 72(14):3439\u20133444","journal-title":"Cancer Res"},{"issue":"6","key":"2_CR39","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","volume":"95","author":"A Loffler","year":"2000","unstructured":"Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM et al (2000) A recombinant bispecific single-chain antibody, CD19\u00d7CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95(6):2098\u20132103","journal-title":"Blood"},{"issue":"5","key":"2_CR40","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/sj.leu.2402890","volume":"17","author":"A Loffler","year":"2003","unstructured":"Loffler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T et al (2003) Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct. Leukemia 17(5):900\u2013909","journal-title":"Leukemia"},{"issue":"16","key":"2_CR41","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","volume":"35","author":"G Martinelli","year":"2017","unstructured":"Martinelli G, Boissel N, Chevallier P, Ottmann O, G\u00f6kbuget N, Topp MS et al (2017) Complete hematologic and molecular response in adult patients with relapsed\/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol 35(16):1795\u20131802","journal-title":"J Clin Oncol"},{"issue":"1","key":"2_CR42","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4049\/jimmunol.131.1.244","volume":"131","author":"LM Nadler","year":"1983","unstructured":"Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF et al (1983) B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 131(1):244\u2013250","journal-title":"J Immunol"},{"issue":"9","key":"2_CR43","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.yexcr.2011.03.010","volume":"317","author":"D Nagorsen","year":"2011","unstructured":"Nagorsen D, Baeuerle PA (2011) Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 317(9):1255\u20131260","journal-title":"Exp Cell Res"},{"issue":"6","key":"2_CR44","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1080\/10428190902943077","volume":"50","author":"D Nagorsen","year":"2009","unstructured":"Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G (2009) Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma 50(6):886\u2013891","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL et al (2018) Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47\u201362","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2_CR46","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","volume":"43","author":"S Offner","year":"2006","unstructured":"Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA (2006) Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 43(6):763\u2013771","journal-title":"Mol Immunol"},{"issue":"3","key":"2_CR47","doi-asserted-by":"publisher","first-page":"738","DOI":"10.18549\/PharmPract.2016.03.738","volume":"14","author":"IK Rayes","year":"2016","unstructured":"Rayes IK, Abduelkarem AR (2016) A qualitative study exploring physicians\u2019 perceptions on the role of community pharmacists in Dubai. Pharm Pract (Granada) 14(3):738","journal-title":"Pharm Pract (Granada)"},{"key":"2_CR48","doi-asserted-by":"crossref","unstructured":"Richard-Carpentier G, Kantarjian HM, Short NJ, Ravandi F, Ferrajoli A, Schroeder HM et al (2018) A phase II study of the hyper-CVAD regimen in sequential combination with blinatumomab as frontline therapy for adults with B-cell acute lymphoblastic leukemia (B-ALL). Blood 132(32)","DOI":"10.1182\/blood-2018-99-117470"},{"key":"2_CR49","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","volume":"14","author":"M Ruella","year":"2016","unstructured":"Ruella M, Maus MV (2016) Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J 14:357\u2013362","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"2_CR50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10020-018-0051-4","volume":"24","author":"K Runcie","year":"2018","unstructured":"Runcie K, Budman DR, John V, Seetharamu N (2018) Bi-specific and tri-specific antibodies\u2014the next big thing in solid tumor therapeutics. Mol Med 24(1):50","journal-title":"Mol Med"},{"issue":"8","key":"2_CR51","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/14712598.2017.1334053","volume":"17","author":"S Sanders","year":"2017","unstructured":"Sanders S, Stewart DA (2017) Targeting non-Hodgkin lymphoma with blinatumomab. Expert Opin Biol Ther 17(8):1013\u20131017","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"2_CR52","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.3324\/haematol.2013.100073","volume":"99","author":"P Schlegel","year":"2014","unstructured":"Schlegel P, Lang P, Zugmaier G, Ebinger M, Kreyenberg H, Witte KE et al (2014) Pediatric posttransplant relapsed\/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 99(7):1212\u20131219","journal-title":"Haematologica"},{"issue":"10","key":"2_CR53","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1200\/JCO.2015.64.9970","volume":"34","author":"NC Smits","year":"2016","unstructured":"Smits NC, Sentman CL (2016) Bispecific T-cell engagers (BiTEs) as treatment of B-cell lymphoma. J Clin Oncol 34(10):1131\u20131133","journal-title":"J Clin Oncol"},{"issue":"12","key":"2_CR54","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G et al (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5(12):1282\u20131295","journal-title":"Cancer Discov"},{"issue":"26","key":"2_CR55","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE et al (2013) Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121(26):5154\u20135157","journal-title":"Blood"},{"issue":"18","key":"2_CR56","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, G\u00f6kbuget N, Goebeler M, Klinger M, Neumann S et al (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol: Off J Am Soc Clin Oncol 29(18):2493\u20132498","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2_CR57","doi-asserted-by":"crossref","unstructured":"Topp M, G\u00f6kbuget N, Zugmaier G, Viardot A, Stelljes M, Neumann S et al (2012) Anti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs overall survival in adult patients with relapsed\/refractory B-precursor acute lymphoblastic leukemia (ALL). Blood 120(21):#670","DOI":"10.1182\/blood.V120.21.670.670"},{"issue":"36","key":"2_CR58","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S et al (2014) Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32(36):4134\u20134140","journal-title":"J Clin Oncol"},{"issue":"1","key":"2_CR59","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, Zugmaier G, O\u2019Brien S, Bargou RC et al (2015a) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16(1):57\u201366","journal-title":"Lancet Oncol"},{"key":"2_CR60","doi-asserted-by":"crossref","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, Zugmaier G, O\u2019Brien S, Bargou RC et al (2015b) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol","DOI":"10.1016\/S1470-2045(14)71170-2"},{"issue":"10","key":"2_CR61","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/jnen\/nly064","volume":"77","author":"M Torre","year":"2018","unstructured":"Torre M, Solomon IH, Sutherland CL, Nikiforow S, DeAngelo DJ, Stone RM et al (2018) Neuropathology of a case with fatal CAR T-cell-associated cerebral edema. J Neuropathol Exp Neurol 77(10):877\u2013882","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"2_CR62","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","volume":"131","author":"MP Velasquez","year":"2018","unstructured":"Velasquez MP, Bonifant CL, Gottschalk S (2018) Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 131(1):30\u201338","journal-title":"Blood"},{"issue":"11","key":"2_CR63","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","volume":"127","author":"A Viardot","year":"2016","unstructured":"Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N et al (2016) Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma. Blood 127(11):1410\u20131416","journal-title":"Blood"},{"key":"2_CR64","doi-asserted-by":"crossref","unstructured":"Von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett T, Rizzari C et al (2016) Phase I\/Phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol. Published online ahead of print at http:\/\/www.jco.org on 3 Oct 2016","DOI":"10.1200\/JCO.2016.67.3301"},{"issue":"7","key":"2_CR65","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/13543784.2018.1492549","volume":"27","author":"MP Watkins","year":"2018","unstructured":"Watkins MP, Bartlett NL (2018) CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas. Expert Opin Investig Drugs 27(7):601\u2013611","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"2_CR66","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1080\/14740338.2017.1338270","volume":"16","author":"AC Wilke","year":"2017","unstructured":"Wilke AC, G\u00f6kbuget N (2017) Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab. Expert Opin Drug Saf 16(10):1191\u20131202","journal-title":"Expert Opin Drug Saf"},{"issue":"18","key":"2_CR67","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/S1359-6446(05)03554-3","volume":"10","author":"E Wolf","year":"2005","unstructured":"Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA (2005) BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 10(18):1237\u20131244","journal-title":"Drug Discov Today"},{"issue":"1","key":"2_CR68","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.1002\/ajh.24594","volume":"92","author":"H Yu","year":"2017","unstructured":"Yu H, Sotillo E, Harrington C, Wertheim G, Paessler M, Maude SL et al (2017) Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. Am J Hematol 92(1):E11\u2013E13","journal-title":"Am J Hematol"},{"key":"2_CR69","doi-asserted-by":"crossref","unstructured":"Zhao Y, Aldoss I, Qu C, Marcucci G, Stein AS, Bhatia R et al (2018) Genomic determinants of response to blinatumomab in relapsed\/refractory (R\/R) B-cell precursor acute lymphoblastic leukemia in adults. Blood 132(1552)","DOI":"10.1182\/blood-2018-99-113604"},{"issue":"24","key":"2_CR70","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","volume":"126","author":"G Zugmaier","year":"2015","unstructured":"Zugmaier G, G\u00f6kbuget N, Klinger M, Viardot A, Stelljes M, Neumann S et al (2015) Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood 126(24):2578\u20132584","journal-title":"Blood"}],"container-title":["Recent Results in Cancer Research","Current Immunotherapeutic Strategies in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-23765-3_2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T18:33:26Z","timestamp":1695148406000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-23765-3_2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"ISBN":["9783030237646","9783030237653"],"references-count":70,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-23765-3_2","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"type":"print","value":"0080-0015"},{"type":"electronic","value":"2197-6767"}],"subject":[],"published":{"date-parts":[[2019,9,1]]},"assertion":[{"value":"1 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}